uploads///Opdivo

Opdivo Could Be Long-Term Growth Driver for Bristol-Myers Squibb

By

Jan. 19 2018, Updated 10:32 a.m. ET

Recent developments

In December 2017, Bristol-Myers Squibb (BMY) and Seattle Genetics (SGEN) presented updated results from the phase 1/2 clinical trial to evaluate Opdivo and Adcetris combination therapy for relapsed or refractory classical Hodgkin lymphoma (or HL). In 1Q17, 2Q17, and 3Q17, Opdivo reported revenues of $1.1 billion, $1.2 billion, and $1.3 billion, respectively.

Article continues below advertisement

Interim results

The results were reported from the phase 1/2 clinical trial constituting 62 candidates with relapsed or refractory HL who were administered Adcetris and Opdivo combination therapy following the failure of frontline therapy.

Candidates with relapsed or refractory HL were treated once every three weeks with up to four cycles of Adcetris and Opdivo combination therapy in the outpatient setting. At the end of the fourth cycle of therapy, candidates were eligible to undergo an ASCT (autologous stem cell transplant).

In the phase 1/2 clinical trial, among 60 response-evaluable patients, 83% of patients had an objective response. 37% of patients achieved a complete response and 13% of patients achieved a partial response. Among the 62 enrolled patients, 58 patients completed the four cycles of the trial therapy, and four patients discontinued therapy prior to completion.

In the clinical trial, in 44% of patients, infusion-related reactions were observed, while 41% were of grade one or two. Presently, Seattle Genetics’ Adcetris is approved for the treatment of individuals with Classical HL who are at high risk of relapse and after the failure of auto-HSCT (hematopoietic stem cell transplantation) or post failure of at least two previous multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates. The FDA (Food and Drug Administration) has also granted accelerated approval of Adcetris for systemic anaplastic large cell lymphoma (or sALCL) post failure of at least one previous multi-agent chemotherapy regimen.

Some drugs indicated for HL include Merck’s (MRK) Keytruda, GlaxoSmithKline’s (GSK) Leukeran, Vinblastine, Vincristine, and others.

The success in the clinical trial will further strengthen Opdivo’s commercialization capabilities and support data for the approval of label expansion. The growth in sales of Opdivo could boost the Vanguard High Dividend Yield ETF (VYM). Bristol-Myers Squibb makes up about ~1.0% of VYM’s total portfolio holding.

Advertisement

More From Market Realist

  • SemiLEDS logo over LED lighting
    Company & Industry Overviews
    There's Still Time to Get in on SemiLEDS (LEDS) Stock
  • Trader on the NYSE
    Company & Industry Overviews
    What Are the Most Expensive Stocks Ever?
  • Michelob Ultra beer
    Company & Industry Overviews
    AB InBev Is the Top Beer Brand Worldwide—Is It a Monopoly?
  • Businesswoman looking out a window
    Company & Industry Overviews
    Shifting Focus: Three Women Investing Funds in 2021
  • CONNECT with Market Realist
  • Link to Facebook
  • Link to Twitter
  • Link to Instagram
  • Link to Email Subscribe
Market Realist Logo
Do Not Sell My Personal Information

© Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.